ETNB

ETNB - 89bio Inc Stock Price, Fair Value and News

$14.84 
Market Closed as of 30 Oct 2025, 04:00 pm ET

ETNB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ETNB Price Action

ETNB RSI Chart

ETNB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ETNB Valuation

ETNB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ETNB Fundamentals

ETNB Revenue

ETNB Earnings

ETNB Profitability

ETNB Investor Care

Revenue & Growth

How 89bio Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2022652.0K1.2M1.7M2.2M
2021---148.0K
ETNB
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
 CEO
 WEBSITE89bio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES45